Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $105,600.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00. Following the transaction, the director directly owned 6,199,863 shares of the company’s stock, valued at approximately $21,823,517.76. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $3.32 on Friday. The firm’s 50-day moving average is $3.40 and its 200-day moving average is $4.12. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.80 and a 52-week high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.47. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -2.77 and a beta of 1.05.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The business’s revenue was down 56.8% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.07 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on RXRX. Bank of America lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. JPMorgan Chase & Co. lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.20.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Allworth Financial LP boosted its position in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after buying an additional 4,403 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $41,000. IFP Advisors Inc boosted its position in Recursion Pharmaceuticals by 81.5% in the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after buying an additional 4,650 shares in the last quarter. Finally, PFG Investments LLC acquired a new position in Recursion Pharmaceuticals in the third quarter valued at about $53,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion highlighted multiple clinical progress points across its AI-enabled pipeline, including positive early data for REC-1245, a new Phase 1 trial for REC-4539, and Phase 2 success for REC-4881 in familial adenomatous polyposis, with FDA discussions underway for a potential registrational path. Article Title
• Positive Sentiment: The company reported a narrower-than-expected Q1 loss, beating analyst EPS estimates, which supports the view that operating results are improving even though the business remains unprofitable. Article Title
• Neutral Sentiment: Needham reaffirmed a Buy rating and set an $8.00 price target, reinforcing a bullish long-term view from one analyst. Article Title
• Neutral Sentiment: Bank of America reiterated a Hold rating, reflecting a more cautious stance and limiting enthusiasm around the stock. Article Title
• Negative Sentiment: Despite the better EPS result, quarterly revenue fell sharply year over year and came in well below expectations, showing that Recursion still faces meaningful commercialization and collaboration revenue headwinds. Article Title
• Negative Sentiment: A director sold 30,000 shares under a pre-arranged 10b5-1 plan, which can add to investor caution even though the sale was routine and relatively small versus his remaining stake. Article Title

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.